Whole genome sequencing analysis of *C. difficile* ribotype 027 (RT027) strains demonstrated that two independent lineages emerged in North America from 2000-2003.^[@R1]^ Comparison with historic, pre-epidemic, RT027 strains showed that both epidemic lineages acquired a mutation in the *gyrA* gene, leading to increased resistance to fluoroquinolone antibiotics. While the development of fluoroquinolone resistance (FQR) has almost certainly played a role in the spread of RT027 strains, FQR has also been observed in non-epidemic *C. difficile* ribotypes and identified in strains dating back to the mid-1980s.^[@R2],[@R3]^ Thus, other factors likely contributed to the emergence of epidemic RT027 strains.

The prevalence of a second *C. difficile* ribotype, RT078, increased 10-fold in hospitals and clinics from 1995-2007 and was associated with increased disease severity.^[@R4]^ However, the mechanisms responsible for increased virulence remain unknown.^[@R5]--[@R8]^ It is noteworthy that RT027 and RT078 lineages are phylogenetically distant from one another ([Extended Data Fig. 1](#F1){ref-type="fig"}), indicating that the evolutionary changes leading to concurrent increases in epidemics and disease severity might have emerged by independent mechanisms.^[@R9]^

Epidemic RT027 and RT078 strains can grow on low concentrations of trehalose {#S1}
============================================================================

Ribotype 027 strains exhibit a competitive advantage over non-RT027 strains *in vitro* and in mouse models of CDI.^[@R10]^ To investigate potential mechanisms for increased fitness, we examined carbon source utilization in an epidemic RT027 isolate (CD2015) using the Biolog 96-well Phenotype MicroArray carbon source plates (see Methods and [Extended Data Table 1](#T1){ref-type="table"}). Out of several carbon sources identified that supported CD2015 growth, we found the disaccharide trehalose increased the growth yield of CD2015 by approximately 5-fold compared to a non-RT027 strain. To examine the specificity of enhanced growth on trehalose across *C. difficile* lineages, 21 strains encompassing 9 ribotypes were grown on a defined minimal medium (DMM) supplemented with glucose or trehalose as the sole carbon source. All *C. difficile* strains grew robustly with 20 mM glucose, however, only epidemic RT027 (n=8) and RT078 (n=3) strains exhibited enhanced growth on an equivalent trehalose concentration (10 mM; [Fig. 1](#F7){ref-type="fig"}). Increasing the trehalose concentration to 50 mM enabled growth in most ribotypes ([Extended Data Fig. 2a](#F2){ref-type="fig"}).

Molecular basis for RT027 growth on low levels of trehalose {#S2}
===========================================================

To identify the genetic basis for enhanced trehalose metabolism, we compared multiple *C. difficile* genomes. All *C. difficile* genomes encode a putative phosphotrehalase enzyme (*treA*) preceded by a transcriptional repressor (*treR*) ([Fig. 2a](#F8){ref-type="fig"}). Phosphotrehalase enzymes metabolize trehalose-6-phosphate into glucose and glucose-6-phosphate. To test whether *treA* was essential for trehalose metabolism, we generated *treA* deletion mutants in the RT027 strain R20291 (R20291Δ*treA*) and the RT012 strain CD630 (CD630Δ*treA*) and grew them in DMM supplemented with 50 mM trehalose. The lack of *treA* prevented growth in both knockout strains that could be complemented by plasmid expression of *treA* ([Extended Data Fig. 2b](#F2){ref-type="fig"}). Thus, *treA* is required to metabolize trehalose.

We next asked if RT027 strains have altered regulation of the *treA* gene when compared to other ribotypes. To test this hypothesis and determine the minimum level of trehalose required to activate *treA* expression, we grew CD2015 (RT027) and CD2048 (RT053) and exposed them to increasing amounts of trehalose. We found that the RT027 strain turned on *treA* expression at 50 μM trehalose, a concentration 500-fold lower than that required to turn on *treA* in RT053 ([Fig. 2b](#F8){ref-type="fig"}). To confirm this phenotype, we took four RT027 strains and four non-RT027 strains and measured expression of *treA* in a single trehalose concentration. Again, RT027 strains exhibited significantly higher *treA* expression than all other ribotypes (P=0.029, [Extended Data Fig. 3](#F3){ref-type="fig"}). These results support the idea that RT027 strains are exquisitely sensitive to low concentrations of trehalose.

Sequence alignment of the trehalose operon across 1,010 sequenced *C. difficile* strains revealed a conserved single nucleotide polymorphism (SNP) within the *treR* gene of all RT027 strains (TreR~RT027~) ([Extended Data Fig. 4a](#F4){ref-type="fig"}). The SNP encodes an L172I amino acid substitution near the predicted effector (trehalose-6-phosphate) binding pocket of TreR ([Fig. 2c](#F8){ref-type="fig"}), a site that is highly conserved across multiple species (93.9% conservation, [Extended Data Fig. 4b](#F4){ref-type="fig"}). This SNP is found not only in every RT027 strain sequenced to date, but is also present in a newly isolated fluoroquinolone sensitive ribotype (RT244) that has caused community-acquired epidemic outbreaks in Australia^[@R11],[@R12]^ and other ribotypes very closely related to RT027, such as RT176 which has caused epidemic outbreaks in the Czech Republic and Poland.^[@R13],[@R14]^ Like RT027 strains, the RT244 strains DL3110 and DL3111 can grow on 10 mM trehalose ([Extended Data Fig. 2c](#F2){ref-type="fig"}).

To determine the types of spontaneous mutations that lead to enhanced trehalose utilization, we cultivated several non-RT027/RT078 strains under low trehalose concentrations in minibioreactors.^[@R10]^ After 3 days of continuous cultivation, 13 independent spontaneous mutants capable of growing on low concentrations (\< 10 mM) of trehalose were isolated. All thirteen mutants contained either nonsense or missense mutations in the *treR* gene ([Extended Data Table 2](#T2){ref-type="table"}).

Impact of trehalose metabolism on disease severity {#S3}
==================================================

To test whether the ability of *C. difficile* RT027 strains to metabolize trehalose impacts disease severity, we performed two different experiments. In the first, humanized microbiota mice were challenged with 10^4^ spores of either R20291 (RT027, n=27) or R20291Δ*treA* (n=28). Following infection, trehalose (5 mM) was provided *ad libitum* in the drinking water and disease progression monitored. The R20291Δ*treA* mutant demonstrated a dramatic decrease in mortality (33.3 vs 78.6%) when compared to R20291 (78% lower risk with R20291Δ*treA*; hazard ratio, 0.22; 95% CI, 0.09 to 0.59; P=0.003, likelihood ratio test P=0.002 ([Fig. 3a](#F9){ref-type="fig"}). In the second experiment, we infected two groups of humanized microbiota mice with RT027 strain R20291. One group received 5 mM trehalose in water as well as a daily gavage of 300 mM trehalose (n=28) to mimic a dose expected in a meal for humans, whereas the control group (n=27) received a water control. Trehalose addition was found to cause increased mortality compared to the RT027 infected mice without dietary trehalose (3-fold increased risk with trehalose; hazard ratio, 3.20; 95% CI, 1.09 to 9.42; P=0.035, likelihood ratio test P=0.026, [Fig 3b](#F9){ref-type="fig"}). Combined, these results show that metabolism of dietary trehalose can contribute to disease severity of RT027 *C. difficile* strains.

To identify the cause of increased disease severity when trehalose is present, we challenged mice with either R20291 or R20291Δ*treA* and provided 5 mM trehalose *ad libitum* in the drinking water. Forty-eight hours post challenge, *C. difficile* load and toxin levels were measured. Over two independent experiments, no significant difference in *C. difficile* numbers were observed, however, a significant increase in relative toxin B levels was detected (median 9.2 X10^4^, IQR 5.1 × 10^4^−1.0 × 10^5^ Vs median 4.1 × 10^4^, IQR 2.3 × 10^4^−4.6 × 10^4^, p=.0268, [Extended Data Fig. 5](#F5){ref-type="fig"}). This increased toxin production could contribute to increased disease severity.

Molecular basis for RT078 growth on low levels of trehalose {#S4}
===========================================================

Molecular basis for RT078 Unlike RT027, RT078 strains do not possess the TreR L172I substitution or other conserved SNPs in the *treRA* operon. To identify sequences of potential relevance to trehalose metabolism, we performed whole genome comparisons. A four-gene insertion was found in all RT078 strains sequenced to date, annotated to encode a second copy of a phosphotrehalase (TreA2, sharing 55% amino acid identity with TreA), a potential trehalose specific PTS system IIBC component transporter (PtsT), a trehalase family protein that is a putative glycan debranching enzyme (TreX), and a second copy of a TreR repressor protein (TreR2, sharing 44% amino acid identity with TreR) (see [Fig. 4a](#F10){ref-type="fig"}). Genomic comparison of publicly available *C. difficile* genomes revealed the four-gene insertion was present in RT078 and the closely related RT033, RT045, RT066, and RT126 ribotypes and absent from reference genomes of any other *C. difficile* lineage ([Extended Data Fig. 6](#F6){ref-type="fig"}).

To test whether the newly acquired transporter (*ptsT*) was responsible for enhanced trehalose metabolism, a *ptsT* deletion mutant was constructed in a RT078 (CD1015) strain. This strain was unable to grow on DMM supplemented with 10 mM trehalose ([Fig. 4b](#F10){ref-type="fig"}), but retained the ability to grow in medium supplemented with 50 mM trehalose ([Extended Data Fig. 2d](#F2){ref-type="fig"}). The growth defect in this deletion mutant (CD1015Δ*ptsT*) was directly due to the lack of *ptsT* since expression of *ptsT* from an inducible promoter could complement growth on 10 mM trehalose ([Fig 4b](#F10){ref-type="fig"}).

We next tested if *ptsT* was sufficient to confer enhanced trehalose utilization in a non-ribotype 078 strain, which fails to grow under low trehalose concentrations. To this end, *ptsT* was expressed from an inducible promoter in strain CD630 (RT012). Expression of *ptsT* was sufficient to allow growth of CD630 in DMM supplemented with 10 mM trehalose ([Fig. 4c](#F10){ref-type="fig"}). Taken together, we conclude that *ptsT* is both necessary and sufficient to support growth on low concentrations of trehalose.

To test whether the expression of *ptsT* could confer a fitness advantage, CD1015 (RT078) was competed against its isogenic CD1015Δ*ptsT* mutant in a human faecal minibioreactor (MBRA) model of CDI.^[@R10]^ Following clindamycin treatment of MBRA communities to enable infection, CD1015 and CD1015Δ*ptsT* strains were added together to each reactor and levels monitored over time. Remarkably, the CD1015 strain was found to be significantly more efficient at competing *in vivo* in the presence of a complex microbiota than the CD1015Δ*ptsT* mutant (mean competitive index of 246 on day 7). To ensure the CD1015Δ*ptsT* loss was due to the absence of *ptsT*, CD1015 was competed against the CD1015Δ*ptsT* mutant complemented with *ptsT* from an inducible vector. After 5 days continuous competition, the wild-type RT078 had a mean competitive index of just 3.7 ([Fig. 4d](#F10){ref-type="fig"}). Hence, *ptsT* provides a competitive fitness advantage to RT078 strains.

Significant amounts of dietary trehalose are observed in the distal gut {#S5}
=======================================================================

Despite the presence of a localized brush border trehalase enzyme in the small intestine, human studies suggest that high levels of trehalose consumption can result in significant amounts reaching the distal ileum and colon.^[@R15]--[@R17]^ To demonstrate that a significant amount of dietary trehalose can survive transit through the small intestine, we gavaged mice with 100 μl (300 mM) trehalose (equivalent to the suggested concentration in ice cream) and measured trehalose levels in the cecum over time. Using clinical *C. difficile* strains as biosensors, we found the level of trehalose to be sufficient to activated *treA* gene expression in the RT027 strain CD2015 but not in RT053 strain CD2048 ([Fig 5a](#F11){ref-type="fig"}). To test whether we could detect a low dietary amount of trehalose, we gavaged antibiotic treated mice with 100 μl (5 mM) trehalose and measured *treA* activation in these same strains. Again, the RT027 strain showed significant *treA* activation ([Fig. 5b](#F11){ref-type="fig"}). Finally, to determine if trehalose is bioavailable in humans at sufficient levels to be utilized by epidemic *C. difficile* isolates, we tested ileostomy effluent from three anonymous donors consuming their normal diets. In 2 of 3 samples, *treA* expression was strongly induced in the RT027 strain CD2015 but not in the RT053 strain CD2048 ([Fig. 5c](#F11){ref-type="fig"}), supporting the notion that levels of trehalose found in food is sufficient to be utilized by epidemic *C. difficile* strains.

Discussion {#S6}
==========

Containing an α,α-1,1-glucoside bond between two α-glucose units, trehalose is a non-reducing and extremely stable sugar, resistant to both high temperatures and acid hydrolysis. Although considered an ideal sugar for use in the food industry, the use of trehalose in the US and Europe was limited prior to 2000 due to high cost of production (\~\$700 Kg^−1^). The innovation of a novel enzymatic method for low cost production from starch made it commercially viable as a food supplement (\~\$3 Kg^−1^).^[@R18]^ Granted GRAS (Generally Recognized As Safe) status by the FDA in 2000 and approved for use in food in Europe in 2001, reported expected usage ranges from concentrations of 2%-11.25% for foods including pasta, ground beef, and ice cream. The widespread adoption and use of trehalose in the diet coincides with the emergence of both RT027 and RT078 outbreaks ([Fig. 6](#F12){ref-type="fig"}).

Several lines of evidence support that dietary trehalose has participated in the spread of epidemic *C. difficile* ribotypes. First, the ability of RT027 and RT078 strains to metabolize trehalose was present prior to epidemic outbreaks. The earliest retrospectively recorded RT027 isolate was the non-epidemic strain CD196, isolated in 1985 in a Paris hospital.^[@R19]^ Three years later in 1988, another non-epidemic strain RT027 (BI1) was isolated in Minneapolis, Minnesota. Both isolates, in addition to every RT027 strain sequenced to date, contain the L172I substitution in TreR. RT078 strains were also present in humans prior to 2001, but epidemic outbreaks were not reported until 2003.^[@R4]^ Second, RT027 and RT078 lineages are phylogenetically distant clades of *C. difficile*, yet have convergently evolved distinct mechanisms to metabolize low levels of trehalose. Third, increased disease severity of a RT027 strain that can metabolize trehalose in our CDI mouse model is consistent with increased virulence of RT027 and RT078 ribotypes observed in patients. Fourth, the ability to metabolize trehalose at lower concentrations confers a competitive growth advantage in the presence of a complex intestinal community. Finally, levels of trehalose in ileostomy fluid from patients eating a normal diet are sufficiently high to be detected by RT027 strains. Based on these observations, we propose the widespread adoption and use of the disaccharide trehalose in the human diet has played a significant role in the emergence of these epidemic and hypervirulent strains.^[@R20]^

Methods {#S7}
=======

Bacterial strains and growth {#S8}
----------------------------

A full list of strains can be found in [Extended Data Table 3](#T3){ref-type="table"}. Carbon source utilization of CD630 (RT012) and CD2015 (clinical RT027) was carried out using Biolog Phenotypic Microarray plates. Growth studies were carried out under anaerobic conditions (5% hydrogen, 90% nitrogen, 5% carbon dioxide). Strains were cultured in overnight in BHI media (Difco) supplemented with 0.5% w/v yeast extract. Growth assays utilized a defined minimal medium (DMM) as described previously^[@R21]^ supplemented with either trehalose or glucose as indicated. Anhydrous tetracycline was used at 500 ng/ml to induce expression of *ptsT* or *treA* from ectopic expression vectors.

Comparative genomics {#S9}
--------------------

To identify unique functional features in RT078 strains, we reviewed publicly available *C. difficile* genomes covering all phylogenetic lineages^[@R9]^ using a tool based on BLASTX comparisons of protein annotations.^[@R22]^ The genomes included in the analysis were PCR RT012 (strain 630, lineage I), RT027 (R20291, lineage II), PCR RT017 (CF5, M68 lineage IV), and RT078 (QCD-23m63, CDM120 lineage V).

Genetic manipulation of *C. difficile* {#S10}
--------------------------------------

Inactivation of *treA* in CD630 was accomplished by group-II intron directed insertion as previously described.^[@R23]^ Primers were designed to target intron to insert at bp 177 of *treA* of CD630 (IBS1.2, EBS1, and EBS2; All primers are described in [Extended Data Table 3](#T3){ref-type="table"}). The resulting *treA* insertion-deletion mutant was verified by PCR using primer pair (CR064-CR065) designed to flank the *treA* insertion site, resulting in a 350bp product for the wild-type gene and a 2.4 kbp product for the gene knockout.

Clean deletions in R20291 and CD1015 were performed using a *pyrE* allelic exchange system as described previously.^[@R24]^ This is the first case of the *pyrE* allelic exchange system being used in the RT078 lineage and required generation of CD1015Δ*pyrE* prior to further deletions. Complementation of *treA* and *ptsT* was carried out using an anhydrous tetracycline inducible system as described previously.^[@R25]^ All plasmid conjugations into *C. difficile* strains were carried out with *E. coli* SD46. Cloning was accomplished with a combination of restriction digest and ligase cycling reactions as described previously.^[@R26]^ Primers and detailed plasmid maps for construction of knockout strains are available at the links provided in [Extended Data Table 3](#T3){ref-type="table"}.

Quantitative real-time PCR with reverse transcription {#S11}
-----------------------------------------------------

Strains were grown overnight and subcultured 1:50 into DMM supplemented with 20 mM succinate. Upon reaching an OD~600~ of 0.2-0.3, indicated concentrations of trehalose were added to the culture. After 30 minutes incubation, *C. difficile* cells were collected by centrifugation, resuspended in RNALater solution (Invitrogen), and stored at −80°C. Cells were resuspended in 1 ml RLT buffer (Qiagen RNeasy Kit) and lysed by bead beating (2 × 1 min) at 4°C followed by RNA extraction per manufacturers' instruction. cDNA was synthesized using Invitrogen Superscript III reverse transcriptase following the recommended protocol. Quantitative PCR reactions were performed in triplicate using Power SYBR Green PCR Master Mix (ABI) with either *C. difficile* 16s (JP048-JP049) or *treA* (CR045-CR046) specific primers. Standard curves of cDNA were run to determine primer efficiencies and calculated as per Pfaffl et al.^[@R27]^ Expression of *treA* was determined using an average of triplicate C~T~ values from each biological sample.

Mouse model of CDI {#S12}
------------------

Humanized microbiota mice (^HMb^mice) were derived from an initial population of germ free C57bl/6 mice stably colonized with human gut microbiota and validated for use as a model of CDI.^28\ HMb^mice aged 6-8 weeks of both sexes were treated with a five-antibiotic cocktail consisting of kanamycin (0.4 mg ml^−1^), gentamicin (0.035 mg ml^−1^), colistin (850 U ml^−1^), metronidazole (0.215 mg ml^−1^), and vancomycin (0.045 mg ml^−1^)) administered *ad libitum* in drinking water for 4 days. Water was switched to antibiotic-free sterile water and 24 hrs later mice were administered an intra-peritoneal (IP) injection of clindamycin (10 mg kg^−1^). After a further 24 hrs, mice were challenged with 10^4^ *C. difficile* spores by oral gavage. Sterile drinking water containing 5 mM trehalose was provided *ad libitum* (for the +/- trehalose study, mice were administered an additional 100 μl oral gavage of 300 mM trehalose daily) and mice were monitored for signs of disease.

In a separate experiment to determine *C. difficile* colonization load and toxin production, mice were euthanized 48 hours following challenge with either R20291 or R20291Δ*treA*. *C. difficile* levels in cecal contents were determined by qPCR of toxin genes.^[@R10]^ Relative toxin levels were assessed using a Vero Cell rounding assay.^[@R10]^ Sample sizes for all experiments were determined using power analysis based upon prior experimental data. No randomization of animals was performed; however, all groups were checked to ensure no significant difference in the age, weight or sex of mice between groups prior to starting experiments. All animal use was approved by the Animal Ethics Committee of Baylor College of Medicine (Protocol no. AN-6675).

Detection of trehalose in cecal contents and human ileostomy fluid {#S13}
------------------------------------------------------------------

Antibiotic treated groups were pre-treated with the 5-antibiotic cocktail for 3 days. Mice were gavaged 100 μl of 5 mM trehalose, 300 mM trehalose or water. Twenty minutes post gavage mice were euthanized, cecal contents harvested and vigorously mixed with 2 volumes/weight ice cold DMM (no carbohydrate). Supernatant was separated by centrifugation, filter sterilized, and reduced in an anaerobic chamber overnight prior to use. Ileostomy effluent from three anonymous donors was self-collected into sterile containers and stored at −20°C until thawed, filter sterilized, and used for assay.

Strains were grown overnight and subcultured 1:50 into DMM supplemented with 20 mM succinate. Upon reaching an OD600 of 0.2-0.3 cells were collected via centrifugation and resuspended in \~300 μL cecal or ileostomy fluid and incubated anaerobically for 30 minutes. Cells were then centrifuged and resuspended in RNAlater (Invitrogen) prior to qRT-PCR analysis.

Bioreactor model for ribotype 078 Δ*ptsT* competition {#S14}
-----------------------------------------------------

Faecal communities were established in continuous-flow minibioreactor arrays as previously described^[@R10]^ using bioreactor defined medium^[@R29]^ without starch (BDM4). Communities were disrupted by addition of clindamycin (250 μg ml^−1^) continuously supplied in the medium for four days. Following clindamycin treatment, communities were supplied BDM4 without clindamycin supplemented with trehalose (5 mM final concentration, BDM4~tre~). After 1 day of growth in BDM4~tre~, to allow washout of clindamycin, communities were challenged with a mixture of exponentially growing CD1015 strains (RT078 wt and Δ*ptsT*). The competitive index (CI) was determined by dividing the proportion of wildtype (wt) cells at the end of the competition by the proportion at the start. The CI of wt:Δ*ptsT* strains was determined by qPCR. The CI of wt vs CD1015ΔptsT::ahTCptsT was calculated by selective plating.

Isolation of spontaneous *treR* mutants {#S15}
---------------------------------------

*C. difficile* strains were inoculated into continuous-flow minibioreactor arrays as previously described^[@R10]^ using bioreactor defined medium^[@R29]^ without starch (BDM4) supplemented with 5mM trehalose (BDM4~tre~). Every 24 hours after the start of the experiment 200 μL PBS with containing 100 mM trehalose was spiked into each minibioreactor. The reactors were sampled daily, serially diluted and plated to DMM agar supplemented with 10 mM trehalose. Resulting colonies were streak purified and the ability to grow on low trehalose (10 mM) verified on plates and in broth culture. The *treR* gene was sequenced and compared to the isogenic parent strain.

Statistics {#S16}
----------

Statistical analyses were performed using R (v. 3.3.2). The Students two sample t-test (2-tailed) was used for comparisons of continuous variables between groups with similar variances; Welch two sample t-test (2-tailed) was used for comparisons of continuous variables between groups with dissimilar variances. P values from multiple comparisons were corrected using the Holm method.^[@R30]^ Wilcoxon rank sum test with continuity correction was used for the toxin assay where data is non-normal. Fold change data from *treA* gene expression experiments were log-normalized prior to statistical analysis. Data were visualized using individual data points and group means. The cox proportional hazards model and likelihood ratio tests were used to test significant differences in survival distributions among *C. difficile*-challenged groups of animals.

Collection of human bio-specimens {#S17}
---------------------------------

For faecal samples, live subjects who were self-described as healthy and had not consumed antibiotics within the previous two months were recruited to provide faecal samples for human faecal bioreactor experiments. Informed consent was obtained prior to collection of samples and no identifying information was obtained along with the sample. Faecal samples were collected in sterile containers, transported to the laboratory on ice in the presence of anaerobic gas packs (BD Biosciences) within 16 hrs of collection, manually homogenized in an anaerobic environment, aliquoted into anaerobic tubes, sealed and stored at −80°C until use. Subjects who had ileostomies placed due to a previous, undisclosed illnesses were recruited to provide ileostomy effluents. Informed consent was obtained prior to collection of samples and no identifying information was obtained along with the sample. After transfer from the ostomy bag to a sterile collection container, ileostomy samples were transported to the laboratory on ice within 12 hrs of collection. Upon receipt, samples were stored at −20°C. Ileostomy donors were recruited through the Ostomy Association of Greater Lansing, and were most likely residents of Lansing, Michigan USA and its surrounding counties. Samples were stored at −80°C or −20°C for 3-4 years prior to use. Samples were randomly selected for testing from a bank of available samples. Samples were collected according to a protocol approved by the Institutional Review Board of Michigan State University (Protocol 10-736SM).

Extended Data {#S18}
=============

![Phylogenetic organization of C. difficile MLST profiles. Maximum likelihood tree based upon concatenated Multi Locus Sequence Typing genes of the 399 current profiles available at <https://pubmlst.org/cdifficile/> .^[@R35]^ Stars indicate position of strains used in this study with red stars indicating sequence types possessing either the treR L172I (ST1, ST41) or 4 gene insertion (ST11). Tree constructed using MEGA7.^[@R36]^](nihms923474f1){#F1}

![Growth of *C. difficle* strains\
**a**, The majority of strains can grow on 50 mM trehalose. Dashed grey line and band indicate mean growth in DMM without a carbon source and s.d. Solid lines indicate mean growth yield (OD600) for groups: Non-RT027/078 (n=10), RT027 (n=8), and RT078 (n=3). **b**, Deletion of *treA* ablates the ability of both CD630 (RT12) and R20291 (RT027) to grow on trehalose. This phenotype can be restored by supplying *treA* on an inducible plasmid (n=3 for each strain/group). **c**, RT244 strains (DL3110 and DL3111) possessing the treR L172I mutation are capable of growth on 10 mM trehalose (n=3 for each strain/group). **d**, CD1015ΔptsT can metabolize 50 mM trehalose (n=4 for each strain/group). For panels a-d points represent biologically independent samples, solid bars are mean.](nihms923474f2){#F2}

![RT027 strains express *treA* at a significantly higher level than non-RT027 strains in the presence of 25 mM trehalose\
Each data point (n=4 Ribotypes per group) represents gene expression from a different, biologically independent, strain and is an average from 2-5 independent experiments. P=0.029, Mann-Whitney-Wilcoxon Test (2 sided).](nihms923474f3){#F3}

![RT027 strains have a L172I mutation at a highly conserved site\
**a**, *treR* genes from available *C. difficile* WGS files on NCBI (accessed 11-May-2017) were identified by tblastn and translated to protein sequences. Sequence fragments \< 240 amino acids were discarded and the remaining 1010 sequences aligned with Clustal Omega^[@R37]^. All 191 sequences containing the L172I SNP also contained the *thyA* gene, a marker for the RT027 lineage. *ThyA* was not found in any other genomes. Numbers indicate number of sequences with corresponding amino acid in that position. Multiple sequence alignment visualization generated with ProfileGrid.^[@R38]^ **b**, The TreR protein sequence from RT027 strain R20291 was blasted against non-*C. difficile* sequences in the NCBI database and the top 99 matches (along with R20291~treR~) aligned with Clustal Omega. The Leucine at position 172 was found to be conserved in 93 of 99 non-C. *difficile* sequences. To confirm the importance of this residue, TreR was blasted against all non-Clostridial sequences in the NCBI database and the top 500 hits saved. Following removal of duplicate species 191 sequences were aligned with Clustal Omega. The Leucine at residue 172 was conserved in 83% of sequences (not shown).](nihms923474f4){#F4}

![A *treA* knockout strain has decreased toxin production 48 hours after infection\
Mice were gavaged 10^4^ spores of either R20291 or R20291Δt*reA* and provided 5 mM trehalose in drinking water. Points represent toxin levels from individual mice (R20291 n=10, R20291Δt*reA* n=11) euthanized 48 hours after infection. Bars are mean. Mice gavaged with R20291Δt*reA* had significantly lower toxin levels (p=.0268 Wilcoxon-Mann-Whitney test (2 sided), median 40960, IQR 23040-46080 Vs 92160, IQR 51200-102400).](nihms923474f5){#F5}

![The 4 gene trehalose insertion is only present in the RT078 lineage\
Artemis comparison tool (ACT) displaying pairwise comparisons between *C. difficile* RT078 genome (M120) sequence and genome sequences from other *C. difficile* ribotypes (ribotypes indicated on the left). Numbers between grey bars indicate the genomic region where the trehalose four gene insert is located (3231169..3237057). Regions of sequence homology are displayed in red. The trehalose four gene insert of RT078 (indicated by the arrow on the top) was observed in RT078, but absent in other ribotypes.](nihms923474f6){#F6}

###### 

Compounds conferring ≥ 1.5-fold growth advantage in Biolog Phenotypic Microarray plates PM1 or PM2.

             Compound                   CD630   CD2015
  ---------- -------------------------- ------- --------
  **PM1**:   N-acetyl-D-glucosamine     \+      \+
             L-proline                  −       −
             D-trehalose                \+      \+
             D-mannose                  \+      \+
             D-sorbitol                 −       \+
             D-mannitol                 \+      \+
             D-fructose                 −       \+
             α-D-glucose                \+      \+
             α-Keto-Butyric acid        \+      −
             L-serine                   \+      −
             L-threonine                −       −
             glycyl-L-proline           −       −
  **PM2**:   N-acetyl-neuraminic acid   \+      \+
             D-arabitol                 −       \+
             arbutin                    \+      \+
             D-melezilose               \+      \+
             salicin                    \+      \+
             D-tagatose                 \+      \+
             D-glucosamine              \+      \+
             β-hydroxy-butyric acid     \+      \+
             α-keto valeric acid        \+      \+
             hydroxy-L-proline          −       \+
             L-leucine                  \+      \+
             L-methionine               −       \+

Results of individual experiment where growth was (+) or was not (−) increased by at least 1.5-fold over DMM control.

###### 

Spontaneous *C. difficile* mutants able to utilize 10 mM trehalose.

  Strain   Ribotype   Nonsense mutation[\*](#TFN2){ref-type="table-fn"}   Missense mutation   Insertions/deletions   Number of independent isolates
  -------- ---------- --------------------------------------------------- ------------------- ---------------------- --------------------------------
  3014     001        18                                                  --                  --                     1
  2012     002        63                                                  --                  --                     1
  2012     002        89                                                  --                  --                     2
  2012     002        15                                                  --                  --                     1
  2012     002        22                                                  --                  --                     1
  2012     002        --                                                  S20I                --                     1
  2012     002        64                                                  --                  --                     1
  2012     002        24                                                  --                  --                     1
  2012     002        20                                                  --                  --                     1
  1014     014        --                                                  S41I, T118K         1                      1
  1014     014        --                                                  T118K               --                     1
  2048     053        70                                                  --                  --                     1

Numbers refer to the position in the consensus TreR amino acid sequence which become a premature stop codon.

###### 

Strains, Primers, and Plasmids.

  Strains                               Ribotype            MLST (Clade)   Note                     Reference
  ------------------------------------- ------------------- -------------- ------------------------ ---------------------------------
  CD630                                 12                  54 (1)         Erythromycin sensitive   ^[@R31]^
  CD630Δ*treA*                          12                  54 (1)                                  This Study
  CD630 pRFP185-P~aTc~-*ptsT*           12                  54 (1)                                  This Study
  CD630Δ*treA* pRFP185-P~aTc-~*treA*    12                  54 (1)                                  This Study
  R20291                                27                  1 (2)                                   ^[@R24]^
  R20291Δ*pyrE*                         27                  1 (2)                                   ^[@R24]^
  R20291Δ*treA*                         27                  1 (2)                                   This Study
  R20291Δ*treA* pRFP185-P~aTC~-*treA*   27                  1 (2)                                   This Study
  CD1015                                78                  11 (5)                                  [†](#TFN3){ref-type="table-fn"}
  CD1015Δ*pyrE*                         78                  11 (5)                                  This Study
  CD1015Δ*ptsT*                         78                  11 (5)                                  This Study
  CD1015Δ*ptsT* pRFP185-P~aTc~*-ptsT*   78                  11 (5)                                  This Study
  VPI10463                              3                   12(1)          High toxin producer      
  CD196                                 27                  1 (2)          Ancestral RT027 strain   ^[@R32]^
  CD1007                                053-163             63 (1)                                  [†](#TFN3){ref-type="table-fn"}
  CD1014                                014-20              2 (1)                                   ^[@R10]^
  CD2012                                2                   8 (1)                                   [†](#TFN3){ref-type="table-fn"}
  CD2018                                unique UM isolate                                           [†](#TFN3){ref-type="table-fn"}
  CD2046                                unique UM isolate                                           [†](#TFN3){ref-type="table-fn"}
  CD2048                                053-163             63 (1)                                  ^[@R10]^
  CD37                                  9                   3 (1)          Non-toxigenic strain     ^[@R33]^
  CD4004                                2                   8 (1)                                   [†](#TFN3){ref-type="table-fn"}
  CD4011                                1                   3 (1)                                   [†](#TFN3){ref-type="table-fn"}
  CD2015                                27                  1 (2)                                   ^[@R10]^
  CD3017                                27                  1 (2)                                   ^[@R10]^
  CD4010                                27                  1 (2)                                   ^[@R10]^
  CD4012                                27                  1 (2)                                   [†](#TFN3){ref-type="table-fn"}
  CD4015                                27                  1 (2)                                   ^[@R10]^
  CD2001                                78                  11 (5)                                  [†](#TFN3){ref-type="table-fn"}
  CD2058                                78                  11 (5)                                  [†](#TFN3){ref-type="table-fn"}
  DL3110                                244                 41 (2)         contains L172I in treR   ^[@R11]^
  DL3111                                244                 41 (2)         contains L172I in treR   ^[@R11]^

  Primers   Note                                                                                                                  Sequence 5′ -- 3′
  --------- -------------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------
  IBS1.2    Insertional deletion of *treA* in CD630                                                                               atatcaagcttttgcaacccacgtcgatcgtgaatagaagattattgtgcgcccagatagggtg
  EBS1      cagattgtacaaatgtggtgataacagataagtcattattattaacttacctttctttgt                                                          
  EBS2      cgcaagtttctaatttcggttttctatcgatagaggaaagtgtct                                                                         
  CR064     CD630 *treA* insertion check                                                                                          gcaacaatgatggtataggtgatataaatgg
  CR065     ggaacagaaccatcaggtttagca                                                                                              
  JCb092    Upstream homology arm R20291 *treA*                            5′ phosphorylated                                      agacctttaaggagggataggggt
  JCb093    5′ phosphorylated                                              aggagaaacgtacataggagtcaacca                            
  JCb094    Downstream homology arm R20291 *treA*                          5′ phosphorylated                                      cctgaaacttatttgaataaattaaactacac
  JCb095    5′ phosphorylated                                              gtttgatactgatggagggcctta                               
  JCb096                                                                                                                          gccctccatcagtatcaaacggggatcctctagagtcgac
  JCb097    Bridging oligos for ligase cycling                                                                                    ctcctatgtacgtttctcctcctgaaacttatttgaataa
  JCb098                                                                                                                          cgaattcgagctcggtacccagacctttaaggagggatag
  JCb135    Upstream homology arm CD1015 *pyrE*                            *Sbfl*                                                 ata[cctgcagg]{.ul}agggacattttttattatcttcag
  JCb136    5′ phosphorylated                                              acaacatcttcagcaattattatctttg                           
  JCb137    Spacer from pMTL-YN2                                           5′ phosphorylated                                      gcggccgctgtatccatatgacc
  JCb138    5′ phosphorylated                                              actagcgccattcgccattcagg                                
  JCb139    Downstream homology arm CD1015 *pyrE*                          5′ phosphorylated                                      gcggccgctgtatccatatgacc
  JCb140    *Ascl*                                                         atat[ggcgcg]{.ul}ccataacattaataaaatttaaaatcaataattat   
  JCb141    Bridging oligos for ligase cycling                                                                                    ataattgctgaagatgttgtgcggccgctgtatccatatg
  JCb142    gaatggcgaatggcgctagttaataaaaacttaattattt                                                                              
  JCb153    Upstream homology arm CD1015 *ptsT*                            *EcoRI*                                                ata[gaattc]{.ul}aaaaacccaaaaatttaacc
  JCb154    *BamHI*                                                        ata[ggatcc]{.ul}atctacttatcctttctcttttttattataag       
  JCb155    Downstream homology arm CD1015 *ptsT*                          *BamHI*                                                ata[ggatcc]{.ul}caaatgacaatatataaatataattcccttgg
  JCb156    *Ncol*                                                         ata[ccatgg]{.ul}cgtggttggtcatggttaca                   
  JCb167    CD1015Δ*ptsT* check                                                                                                   cggaatttcttttatattcatttgg
  JCb168    cccaatttgttggagcactt                                                                                                  
  JCb225    Conformation of *pyrE* knockout/repair                                                                                atgggaatgggcggaataac
  JCb226    gcttggaagcagctacaacaga                                                                                                
  JCb211    CD1015 *pyrE* repair                                           *Notl*                                                 ata[gcggcc]{.ul}gcttacattcctaattccttgaactctc
  JP048     qPCR for C. *difficile* 16S DNA                                                                                       ttgagcgatttacttcggtaaaga
  JP049     ccatcctgtactggctcacct                                                                                                 
  CR045     qPCR for C. *difficile treA* DNA                                                                                      tacgctgatggtcctcgtat
  CR046     cgcctcctttataatctgttttc                                                                                               

  Plasmids                 Reference
  ------------------------ ----------------------------------------------------
  pMTL-YN2                 ^[@R24]^
  pMTL-YN2C                ^[@R24]^
  pMTL-YN4                 ^[@R24]^
  pRPF185                  ^[@R34]^
  **Plasmid Maps**         
  pJC-R20291*treA*KO       <https://benchling.com/s/seq-DANCiRRu7FwNqRJC09iu>
  pJC-CD101*5pyrE*KO       <https://benchling.com/s/seq-Km3QbgAkU66DkNtaOA4R>
  pRFP185-P~aTc~*-ptsT*    <https://benchling.com/s/seq-hKTbvE2pfE8MpvvEqFce>
  pJC-CD1015*pyrE*Repair   <https://benchling.com/s/seq-d25nmFmvSPtR1iQB8vka>
  pRFP185-P~aTc~-*treA*    <https://benchling.com/s/seq-TTthHzlU2fsfRZ94oD9V>
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![Only RT027 and 078 strains show enhanced growth on 10 mM trehalose\
Dashed grey line and band indicate mean growth in DMM without a carbon source and s.d. for all samples (n=21). Solid lines are mean growth yield (OD600) for groups: Non-RT027/078 (n=10), RT027 (n=8), and RT078 (n=3). All points represent biologically independent samples.](nihms923474f7){#F7}

![*treA* is responsible for trehalose metabolism\
**a**, Trehalose metabolism operon found in all *C. difficile* strains; consisting of a phosphotrehalase (*treA*) and its transcriptional regulator (*treR*). **b**, RT027 strains strongly induce *treA* at 50 μM trehalose and at a significantly higher level than non-RT027 strains (n=4 biologically independent samples per trehalose concentration/strain). Bars are average fold increase, error bars are s.d.; p values derived from t-test (2-tailed) and Holm corrected for multiple comparisons. **c**, Structure of TreR monomer highlighting proximity of L172I mutation to trehalose-6-P binding pocket.](nihms923474f8){#F8}

![Trehalose metabolism increases virulence\
**a**, Mice Infected with R20291Δt*reA* (n=27 animals) have significantly attenuated risk of mortality when compared to mice infected with R20291 (n=28 animals) (78% lower risk with Δ*treA* mutant; hazard ratio, 0.22; 95% CI, 0.09 to 0.59; P=0.003). **b**, Mice infected with R20291 (RT027) have a significantly higher risk of mortality when trehalose is supplemented in the diet (n=28 animals) than those with no trehalose supplementation (n=27 animals) (3-fold increased risk with trehalose; hazard ratio, 3.20; 95% CI, 1.09 to 9.42; P=0.035). All statistical tests were 2 sided.](nihms923474f9){#F9}

![*ptsT* enables enhanced trehalose metabolism\
**a**, Structure of horizontally acquired trehalose metabolism module found in RT078 and closely related strains. **b**, Deletion of the trehalose transporter from a clinical RT078 strain (CD1015) ablates its ability to grow on 10 mM trehalose. Expression of *ptsT* from an inducible plasmid restores growth of CD1015ΔptsT on 10 mM trehalose, (CD1015, n=4; CD1015Δ*ptsT*, n=4; CD1015Δ*ptsT::ptsT*, n=5). **c**, Expressing *ptsT* from an inducible plasmid enables enhanced growth of CD630 (RT012) on 10 mM trehalose (CD630 n=3; CD630*::ptsT* n=3). **d**, The *ptsT* provides a competitive advantage in complex microbial communities. Dashed grey line (CI = 1) indicates equal fitness of the competing strains, points above this line represent out-competition by CD1015. All points ([Fig 4b-d](#F10){ref-type="fig"}) represent biologically independent samples, bars are mean, p values derived from t-test (2-tailed) and Holm corrected for multiple comparisons where appropriate.](nihms923474f10){#F10}

![Trehalose can be detected in murine cecum and human ileostomy fluid\
**a**, Twenty minutes post gavage, trehalose reaches high enough levels in the murine cecum to turn on expression of *treA* in RT027 but not non-RT027 in both non-antibiotic and antibiotic treated mice (n=3 animals per trehalose concentration/strain). **b**, trehalose can be detected by RT027 but not non-RT027 in the cecum of antibiotic treated mice gavaged with just 100 μl 5 mM trehalose (n=3 animals per group). **c**, RT027 strains can detect trehalose in 2/3 human ileostomy fluid samples tested from patients eating a normal (no deliberate trehalose addition) diet. Points represent biologically independent replicates, bars are average fold increase, error bars are s.d.](nihms923474f11){#F11}

![Timeline of trehalose adoption and spread of RT027 & RT078 lineages\
Flags indicate reported outbreaks or first reports of ribotype 027 (top) or 078 (bottom) in PubMed. ~†~ Stoke Mandeville outbreaks.](nihms923474f12){#F12}
